Home>All News>BioAnaLab Appoints Geoff Hale as CEO
BioAnaLab Appoints Geoff Hale as CEO
26th April 2005
BioAnaLab Limited, a specialist contract analytical laboratory, has recently appointed Professor Geoff Hale as Chief Executive Officer.
Geoff Hale founded the company in 2002 as a spin out from Oxford University’s Therapeutic Antibody Centre, with the support of Oxford University Innovation Ltd (the university’s technical transfer company) where he has worked for the last 10 years developing a range of monoclonal antibodies for treatment of diseases ranging from leukaemia to multiple sclerosis and diabetes. He has been working part-time as Managing Director since September 2004, and with the continued growth of the company, has now been appointed to the full time post of CEO.
Geoff Hale History
Originally trained as a biochemist at Cambridge University, Geoff has an international reputation in therapeutic immunology and brings a wide range of experience to the company. As a scientist, he has published over 300 articles on the mechanisms of action of antibodies. As a Qualified Person under the new GCP regulations, he has been involved since the early 1990s in the manufacturing, quality control and release of biologics for clinical trials. As a coordinator of clinical trials in transplantation and autoimmune diseases and oncology, he has worked with physicians across the world. Having worked with many different pharmaceutical companies, large and small, and being a co-founder of TolerRx Inc, he is familiar with the pharmaceutical business world.
Geoff stated “I am excited by this opportunity to work more closely with the company I founded which is making rapid growth thanks to the hard work of the dedicated team of scientists. I am also grateful that I am able to continue in a smaller role with the Therapeutic Antibody Centre at Oxford University as we see projects through to fruition”.